Abstract
The basal-bolus insulin regimen in the management of diabetes is essential to achieve the recommended glycosylated hemoglobin (HbA1c) to reduce the incidence or the progression of chronic complications. HbA1c is influenced by either fasting plasma glucose and post-prandial hyperglycemia. Faster Aspart is an insulin Aspart with two additional excipients, L-arginine and niacinamide, which provide a faster subcutaneous absorption, the earlier onset of appearance, and consequently the optimization of post-prandial glucose control. Faster Aspart has been widely investigated in the ‘‘onset’’ clinical trials, which show better post-prandial glycemic excursions and noninferiority compared to insulin Aspart with HbA1c reduction. Clinical evidence demonstrates that faster Aspart is a therapeutic option able to provide clinical benefits over the current rapid-acting insulin analogs in terms of improved meal-related glycaemic control in subjects with diabetes. KEY WORDS post-prandial hyperglycemia; cardiovascular disease; insulin treatment; faster-acting insulin; faster aspart.
Highlights
La terapia insulinica basal-bolus nel diabete mira a sostituire la fisiologica secrezione di insulina e a raggiungere il target di emoglobina glicata (HbA1c) a sua volta associato a riduzione dell’incidenza o rallentamento della progressione delle complicanze croniche
HbA1c is influenced by either fasting plasma glucose and post-prandial hyperglycemia
Faster Aspart has been widely investigated in the ‘‘onset’’ clinical trials, which show better post-prandial glycemic excursions and noninferiority compared to insulin Aspart with HbA1c reduction
Summary
Faster Aspart: l’analogo ad azione ultrarapida che ottimizza il controllo glicemico. Dicembrini Dipartimento di Scienze della Salute, Università degli Studi Magna Graecia, Catanzaro. 2 Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università degli Studi di Firenze Dicembrini Dipartimento di Scienze della Salute, Università degli Studi Magna Graecia, Catanzaro. 2 Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università degli Studi di Firenze
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
